EP0608212A4 - Verfahren zur behandlung viraler infektionen. - Google Patents

Verfahren zur behandlung viraler infektionen.

Info

Publication number
EP0608212A4
EP0608212A4 EP19910915297 EP91915297A EP0608212A4 EP 0608212 A4 EP0608212 A4 EP 0608212A4 EP 19910915297 EP19910915297 EP 19910915297 EP 91915297 A EP91915297 A EP 91915297A EP 0608212 A4 EP0608212 A4 EP 0608212A4
Authority
EP
European Patent Office
Prior art keywords
viral infection
treating viral
treating
infection
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19910915297
Other languages
English (en)
French (fr)
Other versions
EP0608212A1 (de
Inventor
Deborah Ann Rathjen
Roger Aston
Ian Alastair Ramshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Peptide Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Technology Ltd filed Critical Peptide Technology Ltd
Publication of EP0608212A4 publication Critical patent/EP0608212A4/de
Publication of EP0608212A1 publication Critical patent/EP0608212A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP91915297A 1990-08-27 1991-08-27 Verfahren zur behandlung viraler infektionen Ceased EP0608212A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPK197690 1990-08-27
AU1976/90 1990-08-27
PCT/AU1991/000400 WO1992003145A1 (en) 1990-08-27 1991-08-27 Method of treating viral infection

Publications (2)

Publication Number Publication Date
EP0608212A4 true EP0608212A4 (de) 1993-10-20
EP0608212A1 EP0608212A1 (de) 1994-08-03

Family

ID=3774922

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91915297A Ceased EP0608212A1 (de) 1990-08-27 1991-08-27 Verfahren zur behandlung viraler infektionen

Country Status (4)

Country Link
EP (1) EP0608212A1 (de)
JP (1) JPH06500323A (de)
CA (1) CA2090401A1 (de)
WO (1) WO1992003145A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587457A (en) * 1990-03-12 1996-12-24 Peptide Technology Limited Neutrophil stimulating peptides
US6375928B1 (en) * 1990-03-12 2002-04-23 Peptech Limited Neutrophil stimulating peptides
IT1254315B (it) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
ES2121907T3 (es) * 1992-08-28 1998-12-16 Bayer Ag Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
HRP20151440T1 (hr) 2008-12-29 2016-01-29 Trevena, Inc. Efektori beta-arestina i sastavi i metode u kojima se koriste
AU2013215269A1 (en) 2012-01-31 2014-08-21 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
US9518086B2 (en) 2014-02-07 2016-12-13 Trevena, Inc. Crystalline and amorphous forms of a β-arrestin effector
US9611293B2 (en) 2014-05-19 2017-04-04 Trevena, Inc. Synthesis of beta-arrestin effectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0415929A1 (de) * 1988-01-15 1991-03-13 Centocor, Inc. Hetero-unterbindende antikörper und ihre therapeutische benutzung
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards

Also Published As

Publication number Publication date
WO1992003145A1 (en) 1992-03-05
EP0608212A1 (de) 1994-08-03
JPH06500323A (ja) 1994-01-13
CA2090401A1 (en) 1992-02-28

Similar Documents

Publication Publication Date Title
EP0476054A4 (en) Method for treating viral infection
EP0610444A4 (de) Verfahren zur behandlung von viralen erkrankungen.
LTIP863A (en) Aminobenzodiazepines, process for preparing thereof and application for the treatment and prevention of viral diseases
EP0608212A4 (de) Verfahren zur behandlung viraler infektionen.
GB9027968D0 (en) Method of treatment
ZA892308B (en) Method of treating retrovirus infection
GB9304746D0 (en) Treatment of viral infections
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
ZA926963B (en) Method of treating latent herpes viral infections.
EP0431784A3 (en) Methods for treating retroviral infection
AU6559194A (en) Method of treating hepatitis b infection
ZW11693A1 (en) Method of treating viral infections
GB2241958B (en) Treatment process
GB2243602B (en) Treatment process
IE892878L (en) Method of treating viral infections
ZA909265B (en) Methods for treating retroviral infection
IE900940L (en) Treating viral infections
MW8393A1 (en) Method of treating viral infections
ZA936559B (en) Method of treating viral infections
IE892991L (en) Treatment of viral infections
GB9001029D0 (en) Method of treatment
GB9001031D0 (en) Method of treatment
GB9014959D0 (en) Method of treatment
PL286564A1 (en) Method of treatment of extragrade pantaerythrite
GB9026564D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE DK FR GB IT LI SE

17Q First examination report despatched

Effective date: 19960111

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19970726